Form 4: Macrogenics Grants Options to Senior VP

Macrogenics Inc. has granted 30,000 employee stock options to Senior VP of Technical Operations, Thomas Spitznagel, with an exercise price of $1.58.

Summary

• Macrogenics Inc. (MGNX) granted 30,000 employee stock options to Thomas Spitznagel, Senior VP of Technical Operations.
• The options have an exercise price of $1.58 per share.
• The grant date for these options was August 15, 2025.
• The options will vest over time, with 25% becoming exercisable one year after the grant date (August 15, 2026).
• The remaining 75% will vest in 12 substantially equal quarterly installments thereafter.
• The options are set to expire on August 15, 2035.

Sentiment

Score: 7

Explanation: The sentiment is positive as it represents a standard executive compensation grant, aligning management's interests with shareholders and indicating retention of key personnel. It does not, however, signal immediate operational or financial breakthroughs.

Positives

• The grant of stock options aligns the interests of Senior VP Thomas Spitznagel with those of shareholders, incentivizing long-term performance and retention.
• This is a standard form of executive compensation, indicating continued commitment to key management personnel.

Risks

• The value of the granted options is subject to the future market price of Macrogenics Inc. common stock, meaning they could become worthless if the stock price falls below the exercise price.
• Dilution risk exists if all options are exercised, increasing the number of outstanding shares, though this is a common aspect of equity compensation plans.

Future Outlook

The options granted to Thomas Spitznagel are structured with a vesting schedule that extends over several years, with 25% vesting one year after the grant date and the remaining 75% vesting in 12 substantially equal quarterly installments thereafter, indicating a long-term incentive for the executive.

Industry Context

The granting of employee stock options is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages. This practice aims to attract, retain, and motivate key talent by providing them with a direct stake in the company's long-term success and aligning their financial interests with those of shareholders.

Comparison to Industry Standards

• The structure of this option grant, including the vesting schedule and expiration period, is consistent with typical equity compensation plans observed across the biotechnology and pharmaceutical sectors.
• The exercise price of $1.58, while specific to this grant, would be evaluated against the company's stock performance and peer compensation benchmarks at the time of grant to assess its competitiveness within the industry.

Related Party Transactions

• The grant of stock options to Thomas Spitznagel, a Senior VP, constitutes a transaction between the company and a related party (an executive officer).

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also benefit from incentivized management performance.
• Employees: Reinforces the company's commitment to competitive compensation practices, potentially boosting morale and retention.

Next Steps

• The options will begin to vest on August 15, 2026, with subsequent quarterly vesting installments.
• Thomas Spitznagel may choose to exercise vested options at any point before the expiration date of August 15, 2035.

Key Dates

Keywords

Macrogenics, MGNX, Stock Options, SEC Form 4, Insider Transaction, Executive Compensation, Biotechnology, Pharmaceuticals, Equity Grant